Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Merck Scraps Keytruda Trial for Prostate Cancer After Dismal Interim Data

January 27, 2023

[Reuters] Merck & Co Inc. (MRK.N) said it was discontinuing a late-stage trial of its blockbuster immunotherapy Keytruda in some prostate cancer patients after interim data showed it was unlikely to meet the study's main goals; the therapy did not extend survival or help extend the time a patient lives without the disease worsening.

Preclinical Patient-Derived Modeling of Castration-Resistant Prostate Cancer Facilitates Individualized Assessment of Homologous Recombination Repair Deficient Disease

January 26, 2023

[Molecular Oncology] In vitro, castration-resistant prostate cancer (LNCaP) sublines revealed a homologous recombination repair defect and enhanced sensitivity to olaparib and cisplatin due to impaired RAD51 expression and recruitment.

BMX Controls 3βHSD1 and Sex Steroid Biosynthesis in Cancer

January 20, 2023

[Journal Of Clinical Investigation] Researchers showed that phosphorylation of tyrosine 344 occured and was required for 3β-hydroxysteroid dehydrogenase-1 (3βHSD1) cellular activity and generation of Δ4, 3-keto-substrates of 5α-reductase and aromatase, including in patient tissues.

CRISPR Screens Reveal Genetic Determinants of PARP Inhibitor Sensitivity and Resistance in Prostate Cancer

January 20, 2023

[Nature Communications] Scientists performed genome-wide CRISPR-Cas9 knockout screens in BRCA1/2-proficient prostate cancer cells and identified previously unknown genes whose loss had a profound impact on poly (ADP-ribose) polymerase inhibitor response.

Selective Androgen Receptor Degrader (SARD) to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer

January 20, 2023

[Elife] Investigators found and identified a bifunctional small molecule Z15, which was both an effective androen receptor (AR) antagonist and a selective AR degrader.

FASN Multi-Omic Characterization Reveals Metabolic Heterogeneity in Pancreatic and Prostate Adenocarcinoma

January 20, 2023

[Journal of Translational Medicine] To evaluate the association between fatty acid synthase (FASN) expression, methylation, prognosis, and mutational profile in pancreatic ductal adenocarcinoma and prostate cancer, researchers interrogated public databases and surveyed online platforms using TCGA data.

An Antisense Amido-Bridged Nucleic Acid Gapmer Oligonucleotide Targeting SRRM4 Alters REST Splicing and Exhibits Anti-tumor Effects in Small Cell Lung Cancer and Prostate Cancer...

January 20, 2023

[Cancer Cell International] Ser/Arg repetitive matrix 4 (SRRM4) expression and RE1-silencing transcription factor (REST) splicing were analyzed by RT-qPCR and conventional RT-PCR after treating SRRM4 antisense oligonucleotide, and cell viability was analyzed in vitro.

Molecular Mechanisms on How FABP5 Inhibitors Promote Apoptosis-Induction Sensitivity of Prostate Cancer Cells

January 20, 2023

[Cell Biology International] The authors investigated the effect of fatty acid-binding protein 5 (FABP5) inhibitors on apoptosis and studied the relevant mechanisms. Wild type recombinant FABP5 significantly reduced apoptotic cells in 22Rv1 and PC3 by 18% and 42%, respectively.

Artepillin C Overcomes Apalutamide Resistance through Blocking Androgen Signaling in Prostate Cancer Cells

January 20, 2023

[Archives of Biochemistry and Biophysics] To search for compounds which overcame the resistance to apalutamide, scientists established apalutamide-resistant prostate cancer 22Rv1 cells (22Rv1/APA). The 22Rv1/APA cells showed higher androgen receptor expression and androgen sensitivity than parental 22Rv1 cells.

Novel N-Benzyl-2-Oxo-1,2-Dihydrofuro [3,4-D]pyrimidine-3(4H)-Carboxamide as Anticancer Agent: Synthesis, Drug-Likeness, ADMET Profile, DFT and Molecular Modelling against EGFR Target

January 20, 2023

[Heliyon] The anticancer activities of the N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide were determined on human colon cancer and prostate cancer cell lines.

Overexpression of YTHDC2 Contributes to the Progression of Prostate Cancer and Predicts Poor Outcomes in Patients with Prostate Cancer

January 20, 2023

[Journal of Biochemical and Molecular Toxicology] Researchers established stable cell lines, DU145 and PC-3, transfected with either empty vector or the full-length YTH domain-containing protein 2 (YTHDC2) gene and conducted cell function assays in vitro.

The Future of Patient-Derived Xenografts in Prostate Cancer Research

January 20, 2023

[Nature Reviews Urology] Although few prostate cancer patient-derived xenografts (PDXs) are available in large repositories, more PDXs are needed to reflect patient diversity, and to study new treatments and emerging mechanisms of resistance.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.